Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up
- PMID: 26691668
- DOI: 10.1016/j.clgc.2015.11.009
Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up
Abstract
Purpose: To investigate the functional and oncologic outcomes of patients with locally advanced or lymph node (LN) metastatic prostate cancer (PCa) treated by laparoscopic radical prostatectomy (LRP) with extended lymph node dissection (ePLND).
Methods: From June 2004 to March 2014, a total of 232 cases (pT3-4N0-1M0) including 160 locally advanced PCa and 72 LN metastatic PCa who received immediate androgen deprivation therapy after LRP plus ePLND were enrolled onto our study. The patients were followed up for 12 to 124 months. Surgical records, surgical margin status, complications, urinary continence, and oncologic outcomes were presented.
Results: The mean operation time and bleeding were 230 minutes and 105 mL, respectively. The rates of urinary continence were 91.4% and 94.8% at 6 and 12 months, respectively. We observed 122 biochemical recurrent cases. The 5- and 8-year biochemical relapse-free survival rates were 47.3% and 46.7%, respectively. The 5- and 8-year overall and cancer-specific survivals were 81.2%, 80.1%, 90.6%, and 90.6%, respectively. The survival analysis showed that biochemical recurrence-free survival rates were significantly lower for patients with higher Gleason score (77.3% vs. 39.6% vs. 30.8%, P = .003 log rank), higher T stage (55.7% vs. 41.4% vs. 21.4%, P = .039 log rank), positive surgical margin (51.1% vs. 29.3%, P = .000 log rank), and higher CAPRA-S score (68.6% vs. 35.0% vs. 29.2%, P = .000 log rank). There were no significant differences in biochemical relapse-free (40.9% vs. 49.3%, P = .286), overall (75.6% vs. 81.9%, P = .398), and cancer-specific (87.3% vs. 92.1%, P = .284) survival between LN-positive and -negative PCa.
Conclusion: LRP plus ePLND in combination with immediate androgen deprivation therapy is a feasible approach to patients with pT3-4N0-1M0 PCa; favorable functional and oncologic outcomes were presented postoperatively.
Keywords: Biochemical recurrence; Extended lymph node dissection; Laparoscopic radical prostatectomy; Locally advanced prostate cancer; Survival.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution.J Cancer Res Clin Oncol. 2013 May;139(5):871-8. doi: 10.1007/s00432-013-1395-3. Epub 2013 Feb 16. J Cancer Res Clin Oncol. 2013. PMID: 23417085 Free PMC article.
-
Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.Eur Urol. 2017 Feb;71(2):249-256. doi: 10.1016/j.eururo.2016.05.008. Epub 2016 May 18. Eur Urol. 2017. PMID: 27209538
-
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31. Eur Urol. 2016. PMID: 26749093
-
Long-term oncological outcomes after laparoscopic radical prostatectomy.BJU Int. 2013 Feb;111(2):271-80. doi: 10.1111/j.1464-410X.2012.11317.x. Epub 2012 Jul 3. BJU Int. 2013. PMID: 22757970 Review.
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
Cited by
-
Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.Curr Urol Rep. 2017 Jul;18(7):51. doi: 10.1007/s11934-017-0696-5. Curr Urol Rep. 2017. PMID: 28589397 Review.
-
Extraperitoneal laparoscopic versus transperitoneal robot-assisted laparoscopic approaches during radical prostatectomy for low-risk or intermediate-risk prostate cancer.Transl Androl Urol. 2025 Apr 30;14(4):1111-1118. doi: 10.21037/tau-2024-748. Epub 2025 Apr 25. Transl Androl Urol. 2025. PMID: 40376533 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous